{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:55:47Z","timestamp":1787003747184,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shenzhen Medical Research Fund","award":["A2403055"],"award-info":[{"award-number":["A2403055"]}]},{"name":"Shenzhen Science and Technology Program","award":["JCYJ20220530145012027"],"award-info":[{"award-number":["JCYJ20220530145012027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-01472-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:09:47Z","timestamp":1751368187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The molecular subtype based on cell cycle-related gene signature predicts the prognosis and chemotherapy and immunotherapy response in gastric cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Rishun","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songcheng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"1472_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"1472_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/annonc\/mdw040","volume":"27","author":"NY Chia","year":"2016","unstructured":"Chia, N. Y. & Tan, P. Molecular classification of gastric cancer. Ann. Oncol. 27, 763\u2013769 (2016).","journal-title":"Ann. Oncol."},{"key":"1472_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tins.2023.01.003","volume":"46","author":"RM Slominski","year":"2023","unstructured":"Slominski, R. M., Raman, C., Chen, J. Y. & Slominski, A. T. How cancer hijacks the body\u2019s homeostasis through the neuroendocrine system. Trends Neurosci. 46, 263\u2013275 (2023).","journal-title":"Trends Neurosci."},{"key":"1472_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb1529","volume":"9","author":"K Mikule","year":"2007","unstructured":"Mikule, K. et al. Loss of centrosome integrity induces p38\u2013p53-p21-dependent G1-S arrest. Nat. Cell Biol. 9, 160\u2013170 (2007).","journal-title":"Nat. Cell Biol."},{"key":"1472_CR5","doi-asserted-by":"publisher","first-page":"6959","DOI":"10.1038\/s41467-021-27124-8","volume":"12","author":"S Hume","year":"2021","unstructured":"Hume, S. et al. The NUCKS1-SKP2-p21\/p27 axis controls S phase entry. Nat. Commun. 12, 6959 (2021).","journal-title":"Nat. Commun."},{"key":"1472_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/nar\/gkv927","volume":"44","author":"M Fischer","year":"2016","unstructured":"Fischer, M., Quaas, M., Steiner, L. & Engeland, K. The p53\u2013p21-DREAM-CDE\/CHR pathway regulates G2\/M cell cycle genes. Nucleic Acids Res. 44, 164\u2013174 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1472_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1535-6108(02)00126-5","volume":"2","author":"K Degenhardt","year":"2002","unstructured":"Degenhardt, K., Chen, G., Lindsten, T. & White, E. BAX and BAK mediate p53-independent suppression of tumorigenesis. Cancer Cell 2, 193\u2013203 (2002).","journal-title":"Cancer Cell"},{"key":"1472_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.biopha.2017.12.106","volume":"98","author":"L Xue","year":"2018","unstructured":"Xue, L., Wu, Z., Liu, J. & Luo, J. FPHPB inhibits gastric tumor cell proliferation by inducing G2-M cell cycle arrest. Biomed. Pharmacother. 98, 694\u2013700 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"1472_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/PGP.0b013e3182063e71","volume":"30","author":"YH Lee","year":"2011","unstructured":"Lee, Y. H. et al. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Int. J. Gynecol. Pathol. 30, 205\u2013217 (2011).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"1472_CR10","doi-asserted-by":"publisher","first-page":"6412593","DOI":"10.1155\/2020\/6412593","volume":"2020","author":"C Chen","year":"2020","unstructured":"Chen, C. et al. Analysis of the expression of cell division cycle-associated genes and its prognostic significance in human lung carcinoma: A review of the literature databases. Biomed Res. Int. 2020, 6412593 (2020).","journal-title":"Biomed Res. Int."},{"key":"1472_CR11","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/15384101.2021.1922806","volume":"20","author":"N Barnaba","year":"2021","unstructured":"Barnaba, N. & LaRocque, J. R. Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma. Cell Cycle 20, 1041\u20131051 (2021).","journal-title":"Cell Cycle"},{"key":"1472_CR12","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","volume":"22","author":"DA Schaer","year":"2018","unstructured":"Schaer, D. A. et al. The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 22, 2978\u20132994 (2018).","journal-title":"Cell Rep."},{"key":"1472_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel, S. et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature 548, 471\u2013475 (2017).","journal-title":"Nature"},{"key":"1472_CR14","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984\u2013997 (2018).","journal-title":"Cell"},{"key":"1472_CR15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1472_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13073-020-0721-z","volume":"12","author":"J Fu","year":"2020","unstructured":"Fu, J. et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 12, 21 (2020).","journal-title":"Genome Med."},{"key":"1472_CR17","doi-asserted-by":"publisher","first-page":"bbab260","DOI":"10.1093\/bib\/bbab260","volume":"22","author":"D Maeser","year":"2021","unstructured":"Maeser, D., Gruener, R. F. & Huang, R. S. oncoPredict: An R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 22, bbab260 (2021).","journal-title":"Brief Bioinform."},{"key":"1472_CR18","doi-asserted-by":"publisher","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-19-0558","volume":"25","author":"L Liu","year":"2019","unstructured":"Liu, L. et al. Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer. Clin. Cancer Res. 25, 7413\u20137423 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1472_CR19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595, 432\u2013437 (2021).","journal-title":"Nature"},{"key":"1472_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2014.12.038","volume":"358","author":"H Tian","year":"2015","unstructured":"Tian, H. et al. DNA damage response\u2013a double-edged sword in cancer prevention and cancer therapy. Cancer Lett. 358, 8\u201316 (2015).","journal-title":"Cancer Lett."},{"key":"1472_CR21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","volume":"72","author":"T Haider","year":"2020","unstructured":"Haider, T., Pandey, V., Banjare, N., Gupta, P. N. & Soni, V. Drug resistance in cancer: Mechanisms and tackling strategies. Pharmacol. Rep. 72, 1125\u20131151 (2020).","journal-title":"Pharmacol. Rep."},{"key":"1472_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","volume":"631","author":"H Chen","year":"2024","unstructured":"Chen, H. et al. NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance. Nature 631, 663\u2013669 (2024).","journal-title":"Nature"},{"key":"1472_CR23","first-page":"1105","volume":"45","author":"L Graziosi","year":"2019","unstructured":"Graziosi, L., Marino, E. & Donini, A. Survival comparison in gastric cancer patients between 7th and 8th edition of the AJCC TNM staging system: The first western single center experience. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 45, 1105\u20131108 (2019).","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"1472_CR24","doi-asserted-by":"publisher","first-page":"480","DOI":"10.17269\/s41997-018-0102-1","volume":"109","author":"AL Mahar","year":"2018","unstructured":"Mahar, A. L. et al. Evaluating TNM stage prognostic ability in a population-based cohort of gastric adenocarcinoma patients in a low-incidence country. Can. J. Public Health 109, 480\u2013488 (2018).","journal-title":"Can. J. Public Health"},{"key":"1472_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1159\/000529628","volume":"90","author":"A Ibrahim","year":"2023","unstructured":"Ibrahim, A., Miligy, I. M., Toss, M. S., Green, A. R. & Rakha, E. A. High Inner Centromere Protein (INCENP) expression correlates with aggressive features and predicts poor prognosis in patients with invasive breast cancer. Pathobiology 90, 377\u2013388 (2023).","journal-title":"Pathobiology"},{"key":"1472_CR26","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-19-0695","volume":"79","author":"M Sun","year":"2019","unstructured":"Sun, M. et al. Targeting the chromosomal passenger complex subunit INCENP induces polyploidization, apoptosis, and senescence in neuroblastoma. Can. Res. 79, 4937\u20134950 (2019).","journal-title":"Can. Res."},{"key":"1472_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41419-022-04654-7","volume":"13","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2\/STAT1 signal suppression in hepatocellular carcinoma. Cell Death Dis. 13, 213 (2022).","journal-title":"Cell Death Dis."},{"key":"1472_CR28","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202011987","volume":"12","author":"D Zecchin","year":"2020","unstructured":"Zecchin, D. et al. Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer. EMBO Mol. Med. 12, e11987 (2020).","journal-title":"EMBO Mol. Med."},{"key":"1472_CR29","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-20-2125","volume":"81","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. Targeting the IRAK1-S100A9 axis overcomes resistance to paclitaxel in nasopharyngeal carcinoma. Can. Res. 81, 1413\u20131425 (2021).","journal-title":"Can. Res."},{"key":"1472_CR30","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1158\/0008-5472.CAN-17-2445","volume":"78","author":"BY Cheng","year":"2018","unstructured":"Cheng, B. Y. et al. IRAK1 augments cancer stemness and drug resistance via the AP-1\/AKR1B10 signaling cascade in hepatocellular carcinoma. Can. Res. 78, 2332\u20132342 (2018).","journal-title":"Can. Res."},{"key":"1472_CR31","doi-asserted-by":"publisher","first-page":"8746","DOI":"10.1038\/ncomms9746","volume":"6","author":"ZN Wee","year":"2015","unstructured":"Wee, Z. N. et al. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat. Commun. 6, 8746 (2015).","journal-title":"Nat. Commun."},{"key":"1472_CR32","first-page":"138","volume":"10","author":"G Ping","year":"2018","unstructured":"Ping, G. et al. Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer. Am. J. Transl. Res. 10, 138\u2013149 (2018).","journal-title":"Am. J. Transl. Res."},{"key":"1472_CR33","doi-asserted-by":"publisher","first-page":"9325407","DOI":"10.1155\/2019\/9325407","volume":"2019","author":"P Du","year":"2019","unstructured":"Du, P. et al. LncRNA PVT1 mediates antiapoptosis and 5-fluorouracil resistance via increasing Bcl2 expression in gastric cancer. J. Oncol. 2019, 9325407 (2019).","journal-title":"J. Oncol."},{"key":"1472_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41419-023-05710-6","volume":"14","author":"Z Qin","year":"2023","unstructured":"Qin, Z. et al. PVT1 inhibition stimulates anti-tumor immunity, prevents metastasis, and depletes cancer stem cells in squamous cell carcinoma. Cell Death Dis. 14, 187 (2023).","journal-title":"Cell Death Dis."},{"key":"1472_CR35","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423\u20131437 (2013).","journal-title":"Nat. Med."},{"key":"1472_CR36","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/ijms20040840","volume":"20","author":"C Roma-Rodrigues","year":"2019","unstructured":"Roma-Rodrigues, C., Mendes, R., Baptista, P. V. & Fernandes, A. R. Targeting tumor microenvironment for cancer therapy. Int. J. Mol. Sci. 20, 840 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1472_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H., Orhan, A., Christensen, J. P. & G\u00f6genur, I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br. J. Cancer 124, 359\u2013367 (2021).","journal-title":"Br. J. Cancer"},{"key":"1472_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100870","volume":"80","author":"S Sivori","year":"2021","unstructured":"Sivori, S. et al. NK cells and ILCs in tumor immunotherapy. Mol. Aspects Med. 80, 100870 (2021).","journal-title":"Mol. Aspects Med."},{"key":"1472_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka, A. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Cell Res. 27, 109\u2013118 (2017).","journal-title":"Cell Res."},{"key":"1472_CR40","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1158\/0008-5472.CAN-20-3909","volume":"81","author":"DK Ahirwar","year":"2021","unstructured":"Ahirwar, D. K. et al. Slit2 inhibits breast cancer metastasis by activating M1-like phagocytic and antifibrotic macrophages. Can. Res. 81, 5255\u20135267 (2021).","journal-title":"Can. Res."},{"key":"1472_CR41","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","volume":"12","author":"A Rodriguez-Garcia","year":"2021","unstructured":"Rodriguez-Garcia, A. et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat. Commun. 12, 877 (2021).","journal-title":"Nat. Commun."},{"key":"1472_CR42","doi-asserted-by":"publisher","first-page":"e002157","DOI":"10.1136\/jitc-2020-002157","volume":"9","author":"J Niogret","year":"2021","unstructured":"Niogret, J. et al. Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1\/PD-1 efficacy. J. Immunother. Cancer 9, e002157 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1472_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"D-R Wang","year":"2022","unstructured":"Wang, D.-R., Wu, X.-L. & Sun, Y.-L. Therapeutic targets and biomarkers of tumor immunotherapy: Response versus non-response. Signal Transduct. Target. Ther. 7, 331 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1472_CR44","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus, L. et al. FDA approval summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin. Cancer Res. 27, 4685\u20134689 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1472_CR45","doi-asserted-by":"publisher","first-page":"e003091","DOI":"10.1136\/jitc-2021-003091","volume":"10","author":"R Cristescu","year":"2022","unstructured":"Cristescu, R. et al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: A pan-tumor retrospective analysis of participants with advanced solid tumors. J. Immunother. Cancer 10, e003091 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1472_CR46","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science (New York, NY) 362, eaar3593 (2018).","journal-title":"Science (New York, NY)"},{"key":"1472_CR47","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim, D. L., Goodman, A., de Melo, G. D. & Kurzrock, R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39, 154\u2013173 (2021).","journal-title":"Cancer Cell"},{"key":"1472_CR48","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"1472_CR49","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi, S. S. & Badgwell, B. D. Current treatment and recent progress in gastric cancer. CA A Cancer J. Clin. 71, 264\u2013279 (2021).","journal-title":"CA A Cancer J. Clin."},{"key":"1472_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-1-4419-6306-2_20","volume":"678","author":"PM Wigmore","year":"2010","unstructured":"Wigmore, P. M. et al. Effects of 5-FU. Adv. Exp. Med. Biol. 678, 157\u2013164 (2010).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1472_CR51","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.1995.13.10.2643","volume":"13","author":"JE Cortes","year":"1995","unstructured":"Cortes, J. E. & Pazdur, R. Docetaxel. J. Clin. Oncol. 13, 2643\u20132655 (1995).","journal-title":"J. Clin. Oncol."},{"key":"1472_CR52","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver, B. A. How taxol\/paclitaxel kills cancer cells. Mol. Biol. Cell 25, 2677\u20132681 (2014).","journal-title":"Mol. Biol. Cell"},{"key":"1472_CR53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-med-053013-053944","volume":"66","author":"DL Hertz","year":"2015","unstructured":"Hertz, D. L. & Rae, J. Pharmacogenetics of cancer drugs. Annu. Rev. Med. 66, 65\u201381 (2015).","journal-title":"Annu. Rev. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01472-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01472-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01472-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:09:48Z","timestamp":1751368188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01472-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-01472-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work was approved by the Ethics Committee of The Seventh Affiliated Hospital of Sun Yat-sen University (KY-2021-072-01). All patients were informed consent in written form. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"20858"}}